keyword
MENU ▼
Read by QxMD icon Read
search

Shingrix

keyword
https://www.readbyqxmd.com/read/30370455/recombinant-zoster-vaccine-shingrix-%C3%A2-a-review-in-herpes-zoster
#1
Yahiya Y Syed
Shingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged ≥ 50 years. In the pivotal trials in adults aged ≥ 50 years (ZOE-50) and ≥ 70 years (ZOE-70), RZV significantly reduced the risk of HZ and PHN. Its protective efficacy waned minimally over 4 years and was well preserved in adults aged ≥ 70 years...
December 2018: Drugs & Aging
https://www.readbyqxmd.com/read/30277735/recombinant-zoster-vaccine-shingrix-for-the-prevention-of-shingles
#2
Leena Deshpande
No abstract text is available yet for this article.
October 15, 2018: American Family Physician
https://www.readbyqxmd.com/read/30145235/recombinant-zoster-vaccine-shingrix-to-prevent-herpes-zoster
#3
Jacqueline R Sly, Allyssa L Harris
Women ages 50 years and older are at risk for herpes zoster, a reactivated virus from varicella zoster virus (chickenpox) that causes a painful vesicular rash and can result in postherpetic neuralgia. It is estimated that one in three adults will be affected by herpes zoster in their lifetime. Research evidence points to the need to prevent herpes zoster through vaccination. Since 2006, clinicians have been vaccinating adults with zoster vaccine live (brand name Zostavax), but the efficacy of this vaccine wanes with time and advanced age...
October 2018: Nursing for Women's Health
https://www.readbyqxmd.com/read/30130448/cost-effectiveness-of-the-recombinant-zoster-vaccine-in-the-german-population-aged-%C3%A2-60-years-old
#4
Desirée Van Oorschot, Anastassia Anastassopoulou, Barbara Poulsen Nautrup, Lijoy Varghese, Alfred von Krempelhuber, Mohamed Neine, Stéphane Lorenc, Desmond Curran
Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in the German population ≥ 60 years of age (YOA) and to identify the optimal age of vaccination. We used a static, multi-cohort Markov model that followed a hypothetical cohort of 1 million people ≥ 60 YOA life-long after vaccination using German-specific inputs...
August 21, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/30037078/methods-for-measuring-t-cell-memory-to-vaccination-from-mouse-to-man
#5
REVIEW
Amy Flaxman, Katie J Ewer
The development of effective vaccines continues to be a key goal for public health bodies, governments, funding bodies and pharmaceutical companies. With new vaccines such as Shingrix targeting Shingles and Bexsero for Meningitis B, licensed in recent years, today's population can be protected from more infectious diseases than ever before. Despite this, we are yet to license vaccines for some of the deadliest endemic diseases affecting children, such as malaria. In addition, the threat of epidemics caused by emerging pathogens is very real as exemplified by the 2014⁻2016 Ebola outbreak...
July 21, 2018: Vaccines
https://www.readbyqxmd.com/read/30028651/development-of-adjuvanted-recombinant-zoster-vaccine-and-its-implications-for-shingles-prevention
#6
Nicolas Lecrenier, Pierre Beukelaers, Romulo Colindres, Desmond Curran, Carine De Kesel, Jean-Philippe De Saegher, Arnaud M Didierlaurent, Edouard Y Ledent, Johann F Mols, Tomas Mrkvan, Marie Normand-Bayle, Lidia Oostvogels, Fernanda Tavares Da Silva, Ventzislav Vassilev, Carlota Vinals, Alain Brecx
GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix, RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its complications. RZV showed >90% efficacy against HZ, sustained over 4 years of follow-up, in all studied age groups. Areas covered: This article reviews the scientific rationale underlying the design of RZV; the clinical evidence demonstrating immunogenicity, safety, and efficacy in persons 50+; and the public health implications and cost-effectiveness...
July 2018: Expert Review of Vaccines
https://www.readbyqxmd.com/read/29880523/herpes-zoster-subunit-vaccine-for-the-prevention-of-herpes-zoster
#7
REVIEW
Melanie R Symoniak, Pejman Farrokh, Mona A Gandhi, Judianne C Slish
PURPOSE: Published literature on the efficacy and safety of the herpes zoster (HZ) subunit vaccine (HZ/su vaccine) in reducing the risks of HZ and postherpetic neuralgia (PHN) in adults 50 years of age and older, as well as the vaccine's properties and efficacy relative to live attenuated vaccine, is reviewed. SUMMARY: HZ/su vaccine (Shingrix, GlaxoSmithKline) is a recently Food and Drug Administration (FDA)-approved vaccine indicated for the prevention of HZ in adults 50 years of age and older...
June 15, 2018: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/29807711/live-zoster-vaccination-in-an-immunocompromised-patient-leading-to-death-secondary-to-disseminated-varicella-zoster-virus-infection
#8
Kate E Alexander, Philip L Tong, Kristine Macartney, Rohan Beresford, Vicky Sheppeard, Monisha Gupta
In 2016, the live attenuated zoster vaccine (Zostavax, Merck and Co, USA) was introduced into the Australian National Immunisation Program for people aged 70 years who are not significantly immunocompromised. We report the administration of Zostavax in an immunocompromised patient with chronic lymphocytic leukaemia and no evidence of primary varicella zoster virus (VZV) infection. The patient presented with a bilateral vesicular facial rash 22 days after receiving Zostavax and was initially managed as an outpatient with oral acyclovir...
June 22, 2018: Vaccine
https://www.readbyqxmd.com/read/29742283/vaccination-practices-in-dialysis-patients-a-narrative-review
#9
REVIEW
Georges Kosmadakis, Julie Albaret, Enrique Da Costa Correia, Frederic Somda, Didier Aguilera
In a period of turmoil concerning vaccination practices, there is a serious conflict between scientifically reasonable, evidence-based guidelines and the far-fetched rumors or misconceptions concerning the vaccination practices in the general population. When a significant portion of the medical and paramedical personnel may be deliberately unvaccinated against common biological agents, achieving effective vaccination rates in the dialysis population may be complicated. Vaccination rates are unacceptably low in dialysis patients and seroconversion rates are even lower; further, serological follow-up is generally poor...
September 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29491694/pharmaceutical-approval-update
#10
Michele B Kaufman
Zoster vaccine recombinant, adjuvanted (Shingrix) for the prevention of shingles in adults; angiotensin II injection (Giapreza) to increase blood pressure in adults with septic or other distributive shock; and glycopyrrolate inhalation solution (Lonhala Magnair) for the maintenance treatment of chronic obstructive pulmonary disease.
March 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/29457489/shingrix-the-new-adjuvanted-recombinant-herpes-zoster-vaccine
#11
Stephanie F James, Elias B Chahine, Allana J Sucher, Cassandra Hanna
OBJECTIVES: To review the immunogenicity, efficacy, and safety of the herpes zoster subunit vaccine (HZ/su) for use in adult patients for the prevention of shingles. DATA SOURCES: A literature search through PubMed was conducted (June 2008 to October 2017) using the terms shingles vaccine and varicella zoster virus. References from retrieved articles and the prescribing information were also reviewed for any additional material. STUDY SELECTION/DATA EXTRACTION: The literature search was limited to human studies published in English...
July 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29370152/recommendations-of-the-advisory-committee-on-immunization-practices-for-use-of-herpes-zoster-vaccines
#12
Kathleen L Dooling, Angela Guo, Manisha Patel, Grace M Lee, Kelly Moore, Edward A Belongia, Rafael Harpaz
On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01B ), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years...
January 26, 2018: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/29186082/shingrix-an-adjuvanted-recombinant-herpes-zoster-vaccine
#13
(no author information available yet)
No abstract text is available yet for this article.
December 4, 2017: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/28426274/a-critical-appraisal-of-shingrix-a-novel-herpes-zoster-subunit-vaccine-hz-su-or-gsk1437173a-for-varicella-zoster-virus
#14
REVIEW
Tehmina Bharucha, Damien Ming, Judith Breuer
HZ/Su, branded as 'Shingrix', is one of the newest vaccines to be submitted for multi-national regulatory approval. It is targeted to prevent shingles, a global concern with aging populations. A live attenuated vaccine for shingles has been available for over a decade, however it is contraindicated in specific subgroups of people, and there are added concerns regarding long-term immunogenicity. HZ/Su is the first subunit vaccine developed to protect against shingles. This paper provides a critical appraisal of current evidence regarding HZ/Su...
August 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/26865048/the-herpes-zoster-subunit-vaccine
#15
REVIEW
Anthony L Cunningham
INTRODUCTION: Herpes zoster (HZ) causes severe pain and rash in older people and may be complicated by prolonged pain (postherpetic neuralgia; PHN). AREAS COVERED: HZ results from reactivation of latent varicella-zoster virus (VZV) infection, often associated with age related or other causes of decreased T cell immunity. A concentrated live attenuated vaccine boosts this immunity and provides partial protection against HZ, but this decreases with age and declines over 5-8 years...
2016: Expert Opinion on Biological Therapy
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"